Is upadacitinib appropriate for a patient with rheumatoid arthritis and stable mild‑to‑moderate chronic obstructive pulmonary disease?

Upadacitinib in COPD with Rheumatoid Arthritis

Upadacitinib is appropriate for patients with rheumatoid arthritis and stable mild-to-moderate COPD, as there are no specific contraindications for this comorbidity, though vigilance for infections is essential.

Treatment Appropriateness

Upadacitinib 15 mg once daily is approved and effective for rheumatoid arthritis patients who have inadequate response to conventional synthetic DMARDs (csDMARDs) like methotrexate 1, 2. The presence of stable mild-to-moderate COPD does not constitute a contraindication to JAK inhibitor therapy.

Key Considerations for COPD Comorbidity

Infection Risk Assessment:

• The primary concern with JAK inhibitors in COPD patients is the increased susceptibility to respiratory infections 1
• Serious infection rates with upadacitinib are comparable to adalimumab in general RA populations 3
• Patients ≥65 years with cardiovascular risk factors showed higher serious infection rates with JAK inhibitors compared to TNF inhibitors 1
• Upper respiratory tract infections and nasopharyngitis are among the most common adverse events with upadacitinib 3

Specific Contraindications to Consider

According to the 2021 EULAR consensus on JAK inhibitors 1, 4:

Absolute contraindications:

• Severe active infections (acute or chronic)
• Active tuberculosis or untreated latent TB
• Severe hepatic disease (Child-Pugh C)

Relative considerations:

• Severe renal disease requires dose adjustment (though not typically relevant in COPD)
• History of recurrent infections warrants careful evaluation

Treatment Algorithm for RA with COPD

Step 1: Assess RA Disease Activity

• If inadequate response to methotrexate or other csDMARDs, advanced therapy is indicated 2
• Target remission or low disease activity (DAS28-CRP <2.6 or ≤3.2) 2

Step 2: Evaluate COPD Stability

• Confirm COPD is stable (not experiencing frequent exacerbations)
• Ensure no active respiratory infections
• Screen for latent tuberculosis 1

Step 3: Risk Stratification

• Age ≥65 years + cardiovascular risk factors: Consider TNF inhibitor first-line over JAK inhibitor due to higher infection risk 1
• Age <65 years or no significant CV risk factors: Upadacitinib is appropriate 5
• Poor prognostic factors for RA (high autoantibodies, early erosions): Biological DMARD or JAK inhibitor indicated 2

Step 4: Initiate Upadacitinib if Appropriate

• Standard dose: 15 mg once daily 1, 6
• Continue background methotrexate unless contraindicated 2
• Monitor closely for respiratory infections, particularly in first 3-6 months

Efficacy Data Supporting Use

Upadacitinib demonstrates robust efficacy in RA:

• ACR20 response: 64-71% at 12 weeks versus 36% with placebo 7
• DAS28-CRP <2.6: 29-48% versus 6% with placebo 7, 8
• Superior to adalimumab for patient-reported outcomes including pain 8, 9
• Radiographic progression inhibition demonstrated at 26 weeks 8

Safety Monitoring in COPD Patients

Enhanced surveillance required for:

• Respiratory infections: Monitor for new or worsening cough, dyspnea, fever
• Herpes zoster: Higher rates with upadacitinib (3.12 events/100 patient-years) versus TNF inhibitors 10, 3
• Serious infections: 2.62 events/100 patient-years 10

Laboratory monitoring:

• Baseline and periodic complete blood counts
• Liver function tests
• Creatine phosphokinase (CPK) - elevations more common with upadacitinib 8, 3

Common Pitfalls to Avoid

1. Do not withhold effective RA therapy solely due to stable COPD - the guidelines do not list COPD as a contraindication 1, 4

2. Do not ignore age and cardiovascular risk factors - patients ≥65 years with CV risk factors may be better candidates for TNF inhibitors initially 1

3. Do not skip tuberculosis screening - essential before initiating any JAK inhibitor 1, 4

4. Do not use upadacitinib during active COPD exacerbations - wait until respiratory status stabilizes

Alternative Considerations

If concerns about infection risk are substantial:

• TNF inhibitors (adalimumab, etanercept) may be preferred in elderly patients with multiple comorbidities 1
• Other JAK inhibitors (baricitinib, tofacitinib) have similar infection profiles 1
• IL-6 inhibitors (tocilizumab, sarilumab) or abatacept are alternatives 2

Drug Interactions

Important for COPD patients:

• Rifampicin (used for TB prophylaxis) increases upadacitinib metabolism - dose adjustment may be needed 1, 6
• No significant interactions with inhaled corticosteroids or bronchodilators 6
• Systemic corticosteroids for COPD exacerbations can be used but increase infection risk 11